-Ris Y Collier, Ai, Jessica Miller, Nicole P Hachmann, Katherine McMahan, Jinyan Liu, Esther Apraku Bondzie, Lydia Gallup, et al. 2022. “Immunogenicity of the BA.5 Bivalent MRNA Vaccine Boosters.”. BioRxiv : The Preprint Server for Biology.
Abstract
Waning immunity following mRNA vaccination and the emergence of SARS-CoV-2 variants has led to reduced mRNA vaccine efficacy against both symptomatic infection and severe disease. Bivalent mRNA boosters expressing the Omicron BA.5 and ancestral WA1/2020 Spike proteins have been developed and approved, because BA.5 is currently the dominant SARS-CoV-2 variant and substantially evades neutralizing antibodies (NAbs). Our data show that BA.5 NAb titers were comparable following monovalent and bivalent mRNA boosters.